Hisamitsu Pharmaceutical Co., Inc.

4530.T
Drug Manufacturers - Specialty & Generic
2026/03/02 Updated
Market Cap: $2.7B (¥422.4B)
Stock Price: $38.65 (¥6,030)
Exchange Rate: 1 USD = ¥156.01

Stock Price Chart

2026/03/02 Updated
22.37
PER (Price Earnings Ratio)
vs Industry Avg: +12.8
1.57
PBR (Price to Book Ratio)
vs Industry Avg: +0.3
1.46%
Dividend Yield
vs Industry Avg: -1.49%

Price Trend

2026/03/02 Updated
Short-term
5-Day MA
-
Near-term
25-Day MA
-4.10%
Mid-term
75-Day MA
+15.67%
Long-term
200-Day MA
+33.25%

Price & Trading Details

2026/03/02 Updated

PRICE

Previous Close ¥6,030
Open ¥6,031
High ¥6,037
Low ¥6,028
Close ¥6,030

TRADING

Volume 1,699,900
Average Volume 551,732
Turnover ¥103億
Min. Purchase ¥603,000

Analyst Recommendations 2 analysts

Updated 2026/03/01
Strong Buy
0
Buy
0
Hold
2
2
Sell
0
Strong Sell
0
Target Price (Mean)
¥4,250
None
¥4,300
High
¥4,250
Median
¥4,200
Low
-3% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Shareholder Composition

Updated 2026/03/01
29.1%
Insider Holdings
31.9%
Institutional
39.0%
Public Float
92
Institutional Holders
Insider Holdings 29.1%
Institutional 31.9%
Public Float 39.0%

Major Holders

Updated 2026/03/01
Institution Ownership Shares Change
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
1.00%
750.7K -7.21%
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
0.77%
579.5K +1.20%
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
0.63%
472.5K -6.38%
iShares Trust-iShares Core MSCI EAFE ETF
0.46%
342.1K 0.00%
iShares Trust-iShares MSCI EAFE Small-Cap ETF
0.25%
185.6K 0.00%
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
0.21%
156.3K +57.56%

Dividend History 4Years Growth

Updated 2026/03/01
-%
Dividend Yield
¥105
Annual Dividend
+20.0%
YoY Growth
35.5%
Payout Ratio
Year Dividend Change
2025 ¥105 +20.0%
2024 ¥88 +3.2%
2023 ¥85 +0.6%
2022 ¥84 +0.6%
2021 ¥84 -

Financial Performance

2026/03/01 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2022 2023 2024 2025
Income Statement
Revenue ¥120,193M ¥128,330M ¥141,706M ¥156,006M
Gross Profit ¥70,067M ¥72,699M ¥78,970M ¥91,196M
Operating Income ¥9,337M ¥11,600M ¥13,167M ¥18,896M
Pretax Income ¥12,976M ¥16,128M ¥19,204M ¥28,710M
Net Income ¥9,658M ¥11,742M ¥13,969M ¥21,758M
EPS ¥118.84 ¥147.88 ¥181.42 ¥295.57
Operating Margin 7.77% 9.04% 9.29% 12.11%
Balance Sheet
Total Assets ¥302,858M ¥313,917M ¥328,779M ¥343,068M
Total Equity ¥253,165M ¥256,362M ¥264,871M ¥276,822M
Total Liabilities ¥49,693M ¥57,555M ¥63,908M ¥66,246M
Cash ¥129,290M ¥122,154M ¥112,459M ¥114,518M
Interest-bearing Debt ¥2,460M ¥2,295M ¥2,100M ¥3,856M
Equity Ratio 83.59% 81.67% 80.56% 80.69%
D/E Ratio 0.01 0.01 0.01 0.01
Cash Flow
Operating CF ¥19,199M ¥12,727M ¥18,188M ¥18,765M
Investing CF -¥13,060M -¥23,868M -¥2,512M ¥17,563M
Financing CF -¥15,189M -¥14,687M -¥16,691M -¥15,850M
Free CF ¥15,006M ¥4,819M ¥5,152M ¥4,991M
Efficiency
ROE 3.81% 4.58% 5.27% 7.86%
ROA 3.19% 3.74% 4.25% 6.34%

Latest IR Information

Latest News (5 items)

Company Information

English Name Hisamitsu Pharmaceutical Co., Inc.
Japanese Name 久光製薬(株)
Stock Code 4530.T (JPX)
Sector / Industry Healthcare / Drug Manufacturers - Specialty & Generic
Website https://www.global.hisamitsu
Employees 2,799

About

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.

Data provided by Yahoo Finance